Corbus Pharmaceuticals Adds Two Key Executives to Lead its Regulatory and CMC Operations
22 mai 2018 08h00 HE
|
Corbus Pharmaceuticals Holdings, Inc.
— Robert Discordia, Ph.D., named Vice President, Pharmaceutical Development & Manufacturing — — Ross Lobell named Vice President, Regulatory Affairs — Norwood, MA, May 22, 2018 (GLOBE...
Celtaxsys Announces Last Patient, Last Visit in Landmark CF Phase 2b Lung Function Preservation Trial, Clinical Results Expected in July
17 mai 2018 08h00 HE
|
Celtaxsys, Inc.
ATLANTA, May 17, 2018 (GLOBE NEWSWIRE) -- Celtaxsys, Inc., a clinical stage pharmaceutical development company focused on advancing treatments for patients with rare inflammatory diseases, today...
Corbus Pharmaceuticals Announces Acceptance of Three Abstracts for Presentation at EULAR 2018 Annual Meeting
15 mai 2018 08h00 HE
|
Corbus Pharmaceuticals Holdings, Inc.
- Data from Phase 2 one-year open-label extension of lenabasum in systemic sclerosis and 6-month open-label extension data in dermatomyositis studies to be presented - Norwood, MA, May 15,...
Corbus Pharmaceuticals Reports 2018 First Quarter Financial Results and Provides Business Update
10 mai 2018 08h00 HE
|
Corbus Pharmaceuticals Holdings, Inc.
– Company continues to make consistent progress in the clinical development programs of lenabasum, in rare, chronic and serious inflammatory and fibrotic diseases – Norwood, MA, May 10, 2018 ...
Celtaxsys announces the issue of four new patents expanding its pipeline of selective leukotriene B4 modulation anti-inflammatory medicines
01 févr. 2018 08h00 HE
|
Celtaxsys, Inc.
New patents build on previously granted composition of matter protection for acebilustat, with additional intellectual protection for use in cystic fibrosis, as well as new compositions for second...
Celtaxsys Secures Private Financing to Advance Acebilustat Phase 3 Cystic Fibrosis (CF) Program Preparatory Activities
04 janv. 2018 08h00 HE
|
Celtaxsys, Inc.
ATLANTA, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Celtaxsys, Inc., a clinical stage drug development company focused on developing novel therapies for rare inflammatory diseases, today announced the...
ProQR to Present at the Annual Piper Jaffray Healthcare Conference
21 nov. 2017 07h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, the Netherlands, Nov. 21, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.(Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...
Anthera Pharmaceuticals Announces Completion of Recruitment in the Phase 3 RESULT Clinical Study of Sollpura
09 nov. 2017 08h30 HE
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced that patient recruitment is now complete for the Phase 3 RESULT clinical study of...
Thrive Event Raises Over $150K for Claire’s Place Foundation
08 nov. 2017 09h00 HE
|
Claire's Place Foundation
Los Angeles, CA, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Claire’s Place Foundation, a non-profit organization providing support to children and families affected by cystic fibrosis, thanks the founders of...
Anthera Pharmaceuticals Announces Presentation of Blisibimod Data at the American College of Rheumatology Annual Meeting
05 nov. 2017 08h30 HE
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., Nov. 05, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) will present additional findings from the CHABLIS-SC1, Phase 3 clinical study of blisibimod, a novel...